American Vanguard (AVD) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
American Vanguard Reports Fourth Quarter & Full Year 2015 Results
March 1, 2016 4:10 PM ESTNEWPORT BEACH, Calif.--(BUSINESS WIRE)-- American Vanguard Corporation (NYSE: AVD) today announced financial results for the fourth quarter and full year ended December 31, 2015.
Fiscal 2015 Fourth Quarter Financial Highlights versus Fiscal 2014 Fourth Quarter:
Net sales were $84.0 million in Q4 2015 compared to $77.6 million in Q4 2014. Net income was $3.0 million in Q4 2015 compared to $1.8 million in Q4 2014. Earnings per diluted share were $0.10 in Q4 2015 versus $0.06 in Q4 2014.Fiscal 2015 Financial Highlights versus Fiscal 2014:
Net sales were $289.4 million in FY 2015 compared to... MoreAmerican Vanguard Announces Investment in Biological Products & Technologies
March 1, 2016 4:05 PM ESTNEWPORT BEACH, Calif.--(BUSINESS WIRE)-- American Vanguard Corporation (NYSE: AVD) and Bi-PA, today announced that American Vanguard Corporation wholly-owned subsidiary, AMVAC-Netherlands BV, has become an investor in Biological Products for Agriculture (Bi-PA). Bi-PA functions as a product development engine bridging basic research/discovery and end-market commercialization. It accomplishes this commercial development by focusing on optimizing formulations and securing regulatory approval. This investment affords American Vanguard a 15% share of Bi-PAs total enterprise valuation; distribution rights in the Americas for Bi-PAs Vintec® Trichoderma biological fungus control agent and subsequent products; and... More
